Supply Chain
In its semiannual Economic Outlook survey, Premier, Inc., asked hospital supply chain, materials management and C-suite executives to reveal the trends impacting their supply chains over the next year. Here are the top five issues.
Every interventional cardiac cath procedure requires the use of an associated monitoring system. Negotiation of this technology requires a deep understanding of how these systems can be highly configurable, how components can be priced and discounted differently.
Savvy healthcare supply chain leaders must go beyond medical product pricing to achieve the next level of savings for their organizations. Here are 3 areas to consider if you are searching for additional savings.
Are hospitals exploiting the 340B drug discount program? Critics of the federal government's program have some new evidence in the debate over healthcare subsidies.
Attitudes toward healthcare financing have been fairly conservative ever since the general economy collapsed with the stock market in 2008.
Hospitals and health systems try their best to anticipate and meet the demand for specific drugs. But drug shortages - whether due to outbreaks of specific illnesses or unanticipated supply bottlenecks - are a fact of life in the medical world.
The U.S. Department of Health and Human Services will sponsor the advanced development of a next-generation portable ventilator to help fill the need for portable, low-cost, user-friendly and flexible ventilators in a pandemic or other public health emergency.
New research by the Centers for Disease Control and Prevention and Premier, Inc., concludes that the inappropriate use of antibiotics in U.S. hospitals could result in an estimated $163 million in excessive costs.
The incidence for abdominal aortic aneurysms (AAA), a bulging, weakened area of the aorta, has led the U.S. market for AAA repair to increase rapidly. It is currently valued at $600 million annually and is forecasted to grow to $1.6 billion worldwide by 2015.
The 340B program is critical for hospitals and other providers that serve some of our country's poorest and most vulnerable patients. When providers monitor compliance and track 340B drugs properly, the program can fulfill its intended purpose.